EcoDrugPlus

Purinergic Receptor P2y2

Ensembl ID : ENSVVUG00000024610
Gene Symbol: P2RY2
1 Cross references
197 Possible Orthologues:

Receptor Interacting Serine/threonine Kinase 1

Ensembl ID : ENSVVUG00000019070
Gene Symbol: RIPK1
3 Cross references
197 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSVVUG00000018516
Gene Symbol: RPTOR
3 Cross references
209 Possible Orthologues:

Renin

Ensembl ID : ENSVVUG00000014921
Gene Symbol: REN
3 Cross references
218 Possible Orthologues:

Ret Proto-Oncogene

Ensembl ID : ENSVVUG00000021289
Gene Symbol: RET
3 Cross references
204 Possible Orthologues:

Retinoic Acid Receptor Alpha

Ensembl ID : ENSVVUG00000000865
Gene Symbol: RARA
3 Cross references
331 Possible Orthologues:

Retinoic Acid Receptor Beta

Ensembl ID : ENSVVUG00000028201
Gene Symbol: RARB
3 Cross references
450 Possible Orthologues:

Retinoic Acid Receptor Gamma

Ensembl ID : ENSVVUG00000028065
Gene Symbol: RARG
3 Cross references
445 Possible Orthologues:

Retinoid X Receptor Alpha

Ensembl ID : ENSVVUG00000027520
Gene Symbol: RXRA
3 Cross references
244 Possible Orthologues:

Retinoid X Receptor Beta

Ensembl ID : ENSVVUG00000025262
Gene Symbol: RXRB
3 Cross references
234 Possible Orthologues:

Retinoid X Receptor Gamma

Ensembl ID : ENSVVUG00000010121
Gene Symbol: RXRG
3 Cross references
274 Possible Orthologues:

Ribosomal Protein L10a

Ensembl ID : ENSVVUG00000026182
Gene Symbol: RPL10A
2 Cross references
150 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).